AVAIL Study Building a Biobank and Registry for Non-Alcoholic Fatty Liver Disease Using Liver Biopsies and Blood Samples

What this Trial Is About

Researchers are creating a biobank and registry focused on non-alcoholic fatty liver disease NAFLD to help discover new treatments, improve risk assessment, and guide interventions for those at highest risk. This observational study collects liver tissue, blood, urine, and clinical data from adults undergoing standard liver biopsies as well as adults without NAFLD. The goal is to support future research by providing paired biological samples and detailed medical information. Participants include adults scheduled for routine liver biopsies and adults with a body mass index of 25 or higher, with or without type 2 diabetes, but no current NAFLD diagnosis. During the study, additional liver tissue samples will be collected during biopsies for research. Blood and urine samples will also be collected, and a FibroScan will be performed to monitor liver fat and fibrosis over time. Data collection includes baseline and annual follow-ups for up to five years. Participants will be involved in sample collection and undergo FibroScan assessments. Researchers will gather clinical data, histological information, and track changes in liver fat and fibrosis. Safety and data integrity are monitored throughout. The study aims to build a comprehensive resource of biological samples and clinical metadata to facilitate future NAFLD research and improve understanding of disease progression.

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)